Inotiv, Inc. to leverage TruVivo^® 2D+ hepatic system within its Discovery and Translational Sciences business to accelerate development of safer, more effective therapies through human-relevant science

In a joint press release, Inotiv, Inc. announces their strategic initiative to leverage LifeNet Health’s proprietary TruVivo® 2D+ hepatic system within its Discovery and Translational Sciences business to address critical challenges in drug development and enable better predictions of human responses to new therapies.

January 13, 2026 (West Lafayette, IN) — Inotiv, Inc., a leading contract research organization specializing in nonclinical and analytical drug discovery, development services, research models, and related products and services, announces their strategic initiative to leverage LifeNet Health’s proprietary TruVivo 2D+ hepatic system within its Discovery and Translational Sciences business. The TruVivo platform combines primary human hepatocytes with human-derived feeder cells to create a more physiologically relevant in vitro model. This technology provides a stronger foundation for predicting human responses to new therapies and addresses a critical challenge in drug development. Through the use of LifeNet Health’s proprietary platform, Inotiv reinforces its commitment to new approach methodologies that support human-relevant science, enhance translational predictability, and help advance the development of safer, more effective therapies. This collaboration highlights the shared vision of transforming preclinical research through human-relevant technologies.

Read the full press release here: Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery

Learn more about Inotiv, Inc. here: https://www.inotiv.com/